Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression

May 2019

Intravenous brexanolone (Zulresso, zul-REH-soh) will make a splash as the first FDA-approved treatment for postpartum depression.

Brexanolone has a unique mechanism...it mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.

Brexanolone is given as a single 60-hour infusion. It starts to improve depression symptoms 24 to 48 hours after starting the infusion. In comparison, SSRIs take at least 1 to 2 weeks to start working.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Transitions of Care Prevent Med Errors at ICU Transitions of Care
Pumps Be Prepared When Patients Are Admitted With an Intrathecal Pump
Infectious Diseases Consider Switching to Oral Antibiotics in Select Osteomyelitis Patients
New Drugs Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression
New Drugs Be Prepared to Manage the Depression Med Esketamine (Spravato)
Infectious Diseases Watch for Latent Tuberculosis Meds During Transitions of Care
Diabetes Optimize Diabetes Meds for Patients With Concomitant Heart Failure
Substance Use Disorder Have a Plan for Alcohol Use Disorder Meds During Transitions of Care
Respiratory & Allergy Help Guide Safe Use of Neti Pots and Nasal Irrigation

Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression

Get unlimited access through an Enterprise license

Table of Contents